Patents by Inventor Rachel Meyers

Rachel Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060003413
    Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.
    Type: Application
    Filed: June 13, 2005
    Publication date: January 5, 2006
    Inventors: Rachel Meyers, Peter Olandt, Rosana Kapeller-Libermann, Rory Curtis, Mark Williamson, Nadine Weich
  • Patent number: 6979564
    Abstract: The invention provides isolated nucleic acids molecules, designated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, which encode novel fucosyltransferase, seven transmembrane receptor, or RhoGAP family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80090, 52874, 52880, 63497, or 33425 gene has been introduced or disrupted. The invention still further provides isolated 80090, 52874, 52880, 63497, or 33425 proteins, fusion proteins, antigenic peptides and anti-80090, 52874, 52880, 63497, or 33425 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: December 27, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Rachel Meyers
  • Publication number: 20050282189
    Abstract: The invention provides isolated nucleic acids molecules, designated 2150 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2150 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2150 gene has been introduced or disrupted. The invention still further provides isolated 2150 proteins, fusion proteins, antigenic peptides and anti-2150 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 11, 2005
    Publication date: December 22, 2005
    Inventors: Rachel Meyers, Jose Lora
  • Publication number: 20050266470
    Abstract: The invention provides isolated nucleic acids molecules, designated 25501 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25501 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25501 gene has been introduced or disrupted. The invention still further provides isolated 25501 proteins, fusion proteins, antigenic peptides and anti-25501 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 27, 2005
    Publication date: December 1, 2005
    Inventor: Rachel Meyers
  • Publication number: 20050214831
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
    Type: Application
    Filed: February 4, 2005
    Publication date: September 29, 2005
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: John Monahan, Manjula Gannavarapu, Sebastian Hoersch, Shubhangi Kamatkar, Steven Kovats, Rachel Meyers, Michael Morrissey, Peter Olandt, Ami Sen, Petter Veiby, Gordon Mills, Robert Bast, Karen Lu, Rosemarie Schmandt, Xumei Zhao, Karen Glatt
  • Publication number: 20050214893
    Abstract: The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875,46842,33201, 83378,84233,64708, 85041,84234,21617, 55562,23566,33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted.
    Type: Application
    Filed: October 19, 2004
    Publication date: September 29, 2005
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Rory Curtis, Maria Glucksmann, Rajasekhar Bandaru, Rosana Kapeller-Libermann
  • Publication number: 20050203049
    Abstract: The invention provides isolated nucleic acids molecules, designated 47169 and 33935 nucleic acid molecules, which encode novel glycosyl transferases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47169 and 33935 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 47169 or 33935 gene has been introduced or disrupted. The invention still further provides isolated 47169 and 33935 proteins, fusion proteins, antigenic peptides and anti-47169 and anti-33935 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 3, 2005
    Publication date: September 15, 2005
    Inventors: Rachel Meyers, Mark Williamson
  • Publication number: 20050148000
    Abstract: The invention provides isolated nucleic acids molecules, designated 47153 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47153 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47153 gene has been introduced or disrupted. The invention still further provides isolated 47153 proteins, fusion proteins, antigenic peptides and anti-47153 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 22, 2004
    Publication date: July 7, 2005
    Inventors: Rachel Meyers, Julie Rosenfeld
  • Publication number: 20050118608
    Abstract: The invention provides isolated nucleic acids molecules, designated 14815 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14815 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14815 gene has been introduced or disrupted. The invention still further provides isolated 14815 proteins, fusion proteins, antigenic peptides and anti-14815 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 23, 2004
    Publication date: June 2, 2005
    Inventor: Rachel Meyers
  • Patent number: 6897056
    Abstract: The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: May 24, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Immaculada Silos-Santiago
  • Patent number: 6849437
    Abstract: The invention provides isolated nucleic acids molecules, designated 47153 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47153 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47153 gene has been introduced or disrupted. The invention still further provides isolated 47153 proteins, fusion proteins, antigenic peptides and anti-47153 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: February 1, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Julie Beth Rosenfeld
  • Publication number: 20050019838
    Abstract: The invention provides isolated nucleic acids molecules, designated 16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid molecules, which encode novel human membrane-associated protein family members, and human cell surface protein family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or disrupted. The invention still further provides isolated 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins, antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 3, 2004
    Publication date: January 27, 2005
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Maria Glucksmann, Rory Curtis, Rosana Kapeller-Libermann, Rajasekhar Bandaru, Kevin Leiby
  • Publication number: 20040259199
    Abstract: The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 20, 2004
    Publication date: December 23, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Inmaculada Silos-Santiago
  • Publication number: 20040248242
    Abstract: The invention provides isolated nucleic acids molecules, designated 47153 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47153 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47153 gene has been introduced or disrupted. The invention still further provides isolated 47153 proteins, fusion proteins, antigenic peptides and anti-47153 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 28, 2002
    Publication date: December 9, 2004
    Inventors: Rachel Meyers, Julie Beth Rosenfeld
  • Publication number: 20040147004
    Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 9, 2003
    Publication date: July 29, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
  • Publication number: 20040142375
    Abstract: Novel cytidine deaminase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length cytidine deaminase-like proteins, the invention further provides isolated cytidine deaminase-like fusion proteins, antigenic peptides, and anti-cytidine deaminase-like antibodies. The invention also provides cytidine deaminase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an cytidine deaminase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 24, 2004
    Publication date: July 22, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel A. Meyers, Laura A. Rudolph-Owen
  • Patent number: 6730491
    Abstract: The invention provides isolated nucleic acids molecules, designated 2504, 15977, or 14760 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, or 14760 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, or 14760 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, or 14760 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, or 14760 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: May 4, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Rachel A. Meyers, Rory A. J. Curtis
  • Publication number: 20040083496
    Abstract: The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 29, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Rosana Kapeller-Libermann, Immaculada Silos-Santiago
  • Publication number: 20040077010
    Abstract: The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 17, 2003
    Publication date: April 22, 2004
    Applicant: Millennium Pharmaceuticals
    Inventors: Rachel Meyers, William James Cook, Mark Williamson, Laura A. Rudolph-Owen, Ruth Gimeno
  • Patent number: 6723533
    Abstract: Novel cytidine deaminase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length cytidine deaminase-like proteins, the invention further provides isolated cytidine deaminase-like fusion proteins, antigenic peptides, and anti-cytidine deaminase-like antibodies. The invention also provides cytidine deaminase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an cytidine deaminase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: April 20, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel A. Meyers, Laura A. Rudolph-Owen